Similarly, in a lung cancer mouse model CXCR2 inhibition decreased tumor-associated neutrophils, increased anti-tumor T cell activity through enhanced CD8+ T cell activation and increased the therapeutic effect of cisplatin treatment [100]. The gene discussed is CD8A; the disease is neoplasm.